Istaroxime
Sponsors
Windtree Therapeutics Inc., sigma-tau i.f.r. S.p.A., Debiopharm International SA, Lee's Pharmaceutical Limited, Windtree Therapeutics
Conditions
Acute Decompensated Heart FailureCardiogenic ShockHealthyHeart FailureHeart Failure, Congestive
Early Phase 1
Phase 1
Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure
WithdrawnNCT00869115
Start: 2009-06-30Updated: 2014-10-23
Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers
CompletedNCT02477449
Start: 2015-03-31End: 2015-10-31Updated: 2025-08-13
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
Active, not recruitingNCT05975021
Start: 2024-06-01End: 2026-08-31Updated: 2025-08-20
Phase 2
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
CompletedNCT00616161
Start: 2006-08-31End: 2007-08-31Updated: 2008-02-15
Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients
WithdrawnNCT00838253
Start: 2009-06-30Updated: 2014-10-23
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
CompletedNCT02617446
Start: 2015-12-31End: 2019-02-06Updated: 2023-05-24
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
CompletedNCT04325035
Start: 2020-09-28End: 2024-10-30Updated: 2025-02-04
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C (SEISMiC-C)
CompletedCTIS2023-507243-11-02
Start: 2025-01-05End: 2025-07-31Target: 80Updated: 2025-05-20
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
Not yet recruitingNCT07583446
Start: 2026-07-01End: 2028-12-01Target: 600Updated: 2026-05-13